- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 11
The Center for Biosimilars® recaps the top stories for the week of November 11, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 11, 2019.
Number 5: A new study shows the extent to which financial hardship is impacting seriously ill Medicare beneficiaries.
Number 4: During the FT Global Pharmaceutical and Biotechnology Conference, Celltrion gave a look at its plans for CT-P13.
Number 3: Prescription drug prices are now front and center in the push to make health insurance coverage more affordable to provide to American workers.
Number 2: Price hikes alone accounted for most recent spending growth on biologics, according to research presented at the American College of Rheumatology’s 2019 annual meeting.
Number 1: On Monday, the first biosimilar rituximab began to reach US oncology patients.
Finally, last week, our e-newsletter asked whether you are optimistic that Stephen Hahn, MD, will be proactive about biosimilars if he is confirmed as the next FDA Commissioner.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
